Neoadjuvant Treatment with Dual Immune Checkpoint Inhibitors Plus Chemotherapy Produces Numerically Higher Major Pathologic Response Rate in Operable NSCLC
Findings from the NEOSTAR phase II platform study
Oncology News
ESMO oncology news aims to keep you up to date with the developments that affect you and your daily practice.
Make sure you check these pages frequently, or sign up to our newsletter! To sign up for ESMO newsletters, create a myESMO account here and select the newsletters you’d like to receive.
1533 results
Similarity of Molecular Portraits in Synchronous Bilateral Breast Cancers Could be Influenced by Common Environmental Factors
Findings from a large comprehensive analysis do not support the evidence of a common genetic clonal alteration
Mortality From PSA-Detected Localised Prostate Cancer Remains Very Low Regardless of Whether Patients Received Active Monitoring, Prostatectomy, or Radiotherapy
Findings from the ProtecT study after 15 years of follow-up
Nirogacestat Shows Significant Benefit in Patients with Progressing Desmoid Tumours
Findings from the DeFi study
Persistence of FLT3-ITD or NPM1 Variants in the Blood Associated with Increased Relapse and Worse Survival Among Patients with AML in First Remission Prior to Allogeneic HCT
DNA sequencing findings among patients with acute myeloid leukaemia in first remission prior to allogeneic haematopoietic cell transplant
FDA Expands Early Breast Cancer Indication for Abemaciclib with Endocrine Therapy
Evidence for efficacy is based on the results from the monarchE study
HRQoL Data Support the Benefit of Adding Pembrolizumab to Chemotherapy in Patients with Persistent, Recurrent, or Metastatic Cervical Cancer
Health-Related Quality-of-Life data from the KEYNOTE-826 study
KRASG12 Mutations Are Biomarkers for Reduced Overall Survival Benefit of Treatment with Trifluridine/Tipiracil in Patients With mCRC
First proof of genomics-based precision medicine for a chemotherapy in metastatic colorectal cancer
Estimate of the Global Economic Cost of the Most Prevalent Cancers in 204 Countries From 2020 To 2050
Findings from an analytical modelling study
EMA Recommends Granting a Marketing Authorisation for Akeega, Fixed-Dose Combinations of Niraparib/Abiraterone Acetate
It is indicated with prednisone or prednisolone for the treatment of metastatic castration-resistant prostate cancer with BRCA1/2 mutations
Patient Exposure to Anticancer Drugs Subsequently Withdrawn from the FDA Accelerated Approval Programme Due to Lack of Benefit
Findings from a cross-sectional study
Neoadjuvant Followed by Adjuvant Pembrolizumab Prolongs Event-Free Survival Compared to Adjuvant Treatment Only in High-Risk, Resectable Stage III or IV Melanoma
Findings from the S1801 study